Comparative Pharmacology
Head-to-head clinical analysis: HECTOROL versus RAYALDEE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HECTOROL versus RAYALDEE.
HECTOROL vs RAYALDEE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic vitamin D analog that binds to vitamin D receptors (VDR), increasing intestinal absorption of calcium and phosphate, and promoting bone mineralization. Also suppresses parathyroid hormone (PTH) production.
Rayaldee (calcifediol) is a vitamin D3 analog that is converted to the active hormone calcitriol by 1-alpha-hydroxylase in the kidney. It acts as a vitamin D receptor agonist, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and suppressing parathyroid hormone (PTH) secretion. In CKD patients, it lowers elevated PTH levels.
0.5 to 1.5 mcg intravenously three times weekly during hemodialysis; adjust to maintain serum intact PTH within target range (1.5 to 3 times upper limit of normal). Initial dose: 0.5 mcg three times weekly; may increase by 0.25 to 0.5 mcg at 2- to 4-week intervals.
30 mcg orally once daily at bedtime.
None Documented
None Documented
Terminal elimination half-life is approximately 5.0 hours in healthy adults; prolonged in patients with hepatic impairment.
Terminal elimination half-life is approximately 14-19 hours, reflecting the extended-release formulation designed for once-daily dosing.
Primarily hepatic metabolism followed by biliary excretion; renal excretion accounts for <2% of unchanged drug.
Primarily fecal via biliary excretion (70-80%); renal excretion accounts for <10% of total clearance.
Category C
Category C
Vitamin D Analog
Vitamin D Analog